Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biomarker Legislation Gets Public Marketing Campaign

This article was originally published in The Pink Sheet Daily

Executive Summary

Newspaper ad from Manhattan Institute picks up on themes contained in think tank's recent Project FDA report aimed at speeding development and use of biomarkers.

You may also be interested in...



Biomarkers Qualification: Can FDA Get Rolling Before A Push From Congress?

FDA has been reluctant to lay out evidentiary standards for biomarker qualification, but its call for information on promising candidates may be an initial step toward creating such a framework.

FDA Cancer Center’s New ‘Projects’ Focus On Early Endpoints; Asian American, Native Hawaiian Populations

Launched in 2023, Project Endpoint focuses on advancing understanding of early, novel endpoints, while Project ASIATICA aims to bring greater awareness of challenges and health disparities faced by Asian American, Native Hawaiian, and Other Pacific Islander patients with cancer.

Patient Assistance Programs From Pharma Companies Need Streamlining, US Senators Say

BMS CEO Boerner acknowledged the complexity of patient assistance programs, and the need for simplification, during a Senate hearing. CEOs of J&J and Merck also tout their patient assistance programs as showing the firms’ commitment to helping patients access drugs they cannot afford.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS077877

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel